中和抗体
病毒学
表位
抗体
效价
严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)
病毒
中和
2019年冠状病毒病(COVID-19)
生物
免疫学
医学
疾病
传染病(医学专业)
病理
作者
Fengze Wang,Li Li,Yang Dou,Rui Shi,Xiaomin Duan,Hongchuan Liu,Jing Zhang,Dandan Liu,Jing Wu,Yang He,Jun Lei,Lan Bai,Hui Feng,Jinghua Yan
标识
DOI:10.1080/22221751.2022.2032374
摘要
The neutralizing antibody is a potential therapeutic for the ongoing COVID-19 pandemic. As an antiviral agent, numerous mAbs recognize the epitopes that overlap with ACE2-binding sites in the SARS-CoV-2-RBD. Some studies have shown that residual changes on the spike protein can significantly decrease the efficiency of neutralizing antibodies. To address this issue, a therapeutic cocktail could be an effective countermeasure. In the present study, we isolated a fully human neutralizing antibody, JS026, from a convalescent patient. The comparative analysis revealed that JS026 binding to SARS-CoV-2-RBD mainly located between epitopes for class 2 and class 3 mAbs as opposed to that of class 1 (etesevimab) antibodies. A cocktail of etesevimab and JS026 increased neutralizing efficacy against both wild-type SARS-CoV-2 and the recent emergence of Alpha, Beta, Gamma, and Delta variants. JS026 and the cocktail reduced virus titers in the infected lungs of hACE2 transgenic mice and relieved pathological changes. These findings would benefit antibody-based therapeutic countermeasures in the treatment of COVID-19.
科研通智能强力驱动
Strongly Powered by AbleSci AI